Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | TYR | P14679 | 2/20 | 0.58 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.58 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.58 |
| ▸ | ERN1 | O75460 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15614302 | 0.85 | ERN1 (0.58) | ALDH1A1TYRTRIM24TRIM33ERN1 | |
| SCHEMBL4261526 | 0.82 | ERN1 (0.43) | ALDH1A1ERN1HTTCYP1A2MAPT | |
| SCHEMBL25120915 | 0.82 | ALDH1A1 (0.40) | ALDH1A1TYRTRIM24TRIM33ERN1 | |
| SCHEMBL2467986 | 0.81 | CYP1A2 (0.44) | ALDH1A1TYRTRIM24TRIM33HTT | |
| SCHEMBL12133990 | 0.80 | PDE2A (0.40) | ALDH1A1TYRTRIM24TRIM33ERN1 | |
| SCHEMBL24172496 | 0.78 | ADRA1A (0.62) | ALDH1A1TYRTRIM24TRIM33ERN1 | |
| SCHEMBL12672585 | 0.78 | ALDH1A1 (0.70) | ALDH1A1TYRTRIM24TRIM33ERN1 | |
| SCHEMBL29957021 | 0.78 | ALDH1A1 (0.70) | ALDH1A1TYRTRIM24TRIM33ERN1 | |
| SCHEMBL490211 | 0.77 | THRB (0.53) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL490210 | 0.77 | THRB (0.53) | ALDH1A1MAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387603-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-5773456-A | EMPHYSEMA, RHEUMATOID ARTHRITIS AND PANCREATITIS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5578623-A | DRUGS FOR TREATMENT OF ARTHRITIS, PANCREATITIS, CYSTIC FIBROSIS, BRONCHITIS, RESPIRATORY DISORDERS | STERLING WINTHROP INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5464852-A | Used in treatment of degenerative diseases | STERLING WINTHROP INC. (US) | 1995-11-07 | — | — | US | disclosed |
| US-5380737-A | Enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0542371-A1 | Saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | disclosed |
| EP-0352672-A2 | Process for the preparation of alkenyl aromatic compounds | BASF Aktiengesellschaft (DE) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | ALDH1A1 125/4885TYR 4377/4885TRIM24 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.